Group One Trading
BCLI

Group One Trading’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Group One Trading’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,133
Closed -$21.2K – 7264
2024
Q3 		$21.2K Hold
6,133
– – ﹤0.01% 5202
2024
Q2 		$31.1K Buy
+6,133
New +$46K ﹤0.01% 4894
2024
Q1 		– Sell
-67
Closed -$273 – 7046
2023
Q4 		$273 Sell
67
-6,406
-99% -$19.2K ﹤0.01% 7142
2023
Q3 		$19.4K Buy
6,473
+2,460
+61% +$55.9K ﹤0.01% 5906
2023
Q2 		$124K Buy
4,013
+20
+0.5% +$829 ﹤0.01% 4398
2023
Q1 		$198K Buy
3,993
+2,693
+207% +$78.1K ﹤0.01% 3691
2022
Q4 		$32K Buy
1,300
+87
+7% +$3.25K ﹤0.01% 5298
2022
Q3 		$80K Buy
1,213
+813
+203% +$40.8K ﹤0.01% 4983
2022
Q2 		$17K Sell
400
-100
-20% -$4.5K ﹤0.01% 6394
2022
Q1 		$25K Sell
500
-1,533
-75% -$75.3K ﹤0.01% 6603
2021
Q4 		$122K Sell
2,033
-2,434
-54% -$120K ﹤0.01% 5548
2021
Q3 		$221K Sell
4,467
-2,646
-37% -$139K ﹤0.01% 5063
2021
Q2 		$405K Sell
7,113
-4,374
-38% -$234K ﹤0.01% 4460
2021
Q1 		$660K Sell
11,487
-2,940
-20% -$222K ﹤0.01% 3716
2020
Q4 		$979K Buy
14,427
+9,514
+194% +$1.3M ﹤0.01% 2659
2020
Q3 		$1.25M Sell
4,913
-4,694
-49% -$961K ﹤0.01% 1999
2020
Q2 		$1.61M Buy
9,607
+4,394
+84% +$474K 0.01% 1622
2020
Q1 		$363K Buy
5,213
+820
+19% +$64K ﹤0.01% 2281
2019
Q4 		$282K Sell
4,393
-8,614
-66% -$500K ﹤0.01% 2912
2019
Q3 		$761K Sell
13,007
-373
-3% -$22K 0.01% 1982
2019
Q2 		$793K Buy
13,380
+6,367
+91% +$371K 0.01% 1755
2019
Q1 		$457K Buy
7,013
+6,746
+2,527% +$384K 0.01% 2021
2018
Q4 		$14K Buy
+267
New +$13.2K ﹤0.01% 4148
2018
Q1 		– Sell
-33
Closed -$2K – 4829
2017
Q4 		$2K Buy
+33
New +$1.97K ﹤0.01% 4682
2017
Q2 		– Sell
-107
Closed -$7K – 4738
2017
Q1 		$7K Sell
107
-46
-30% -$2.39K ﹤0.01% 4203
2016
Q4 		$6K Buy
+153
New +$5.3K ﹤0.01% 4059

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Group One Trading's BCLI Position: Q4 2024 in Review

Group One Trading sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 3,117 shares — an estimated $5.76K sold.

Group One Trading first reported a position in BCLI in Q2 2015 and held it in 21 quarters. The position peaked at $537K in Q1 2023. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.

  • Group One Trading reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
  • Group One Trading sold 3,117 BRAINSTORM CELL THERAPUTC shares in Q4 2024, an estimated $5.76K.
  • Group One Trading first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2015 and held it in 21 quarters.
  • Group One Trading's BRAINSTORM CELL THERAPUTC position peaked at $537K in Q1 2023.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.

Based on Group One Trading's 13F filing for Q4 2024, filed 14 Feb 2025.